Repeated Alpha1H treatments creates long-term protection against bladder tumor growth in mice

On March 18, 2021 Hamlet Pharma reported that new treatment advances in an experimental model of bladder cancer (Press release, HAMLET Pharma, MAR 18, 2021, View Source;utm_medium=rss&utm_campaign=repeated-alpha1h-treatments-creates-long-term-protection-against-bladder-tumor-growth-in-mice [SID1234576937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A potent treatment effect of Alpha1H has previously been reported in mice with bladder cancer. We now show that continued treatment can provide long-term protection as well. Repeated treatment prevented tumor growth and the bladders remained similar to the control group without tumors.

In contrast, mice treated with placebo showed rapid tumor progression and severe disease after 12 days. The first round of Alpha1H treatment prevented tumor development for 4 weeks and long-term protection was achieved when treatment was repeated at 4-week intervals, as evidenced by marked differences in tumor size, pathology score, biomarkers and gene expression.

Cancer is often a chronic condition and several rounds of treatment are usually necessary. The results presented here suggest that repeated Alpha1H treatment regimens may be beneficial to ensure long-term protection against bladder cancer. This needs further validation in future clinical trials.

"Repeated treatment rounds appeared to maintain a high degree of protection against tumor progression in mice", says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.

"This information is important for the design of future clinical trials", says Mats Persson, CEO of Hamlet Pharma Ltd.

This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact persons set out above, on March 18, 2021 at 08.45 CET.